Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Sponsor: ICON Bioscience Inc
Listed as NCT02547623, this PHASE3 trial focuses on Cataract and remains completed. Sponsored by ICON Bioscience Inc, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ICON Bioscience Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Cincinnati, United States , Edgewood, United States , Garden City, United States , Glendora, United States , Hemet, United States , Laguna Hills, United States , Mt. Pleasant, United States , Newport Beach, United States , Pennington, United States , Salt Lake City, United States and 1 more location